Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Conformational Sampling of the Intrinsically Disordered C-Terminal Tail of DERA Is Important for Enzyme Catalysis.

Schulte M, Petrović D, Neudecker P, Hartmann R, Pietruszka J, Willbold S, Willbold D, Panwalkar V.

ACS Catal. 2018 May 4;8(5):3971-3984. doi: 10.1021/acscatal.7b04408. Epub 2018 Mar 27.

2.

Origin of metastable oligomers and their effects on amyloid fibril self-assembly.

Hasecke F, Miti T, Perez C, Barton J, Schölzel D, Gremer L, Grüning CSR, Matthews G, Meisl G, Knowles TPJ, Willbold D, Neudecker P, Heise H, Ullah G, Hoyer W, Muschol M.

Chem Sci. 2018 Jun 13;9(27):5937-5948. doi: 10.1039/c8sc01479e. eCollection 2018 Jul 21.

3.

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.

Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D.

Mol Neurobiol. 2018 Jul 12. doi: 10.1007/s12035-018-1209-3. [Epub ahead of print]

PMID:
30003517
4.

Mechanistic Basis of the Fast Dark Recovery of the Short LOV Protein DsLOV from Dinoroseobacter shibae.

Fettweiss T, Röllen K, Granzin J, Reiners O, Endres S, Drepper T, Willbold D, Jaeger KE, Batra-Safferling R, Krauss U.

Biochemistry. 2018 Aug 14;57(32):4833-4847. doi: 10.1021/acs.biochem.8b00645. Epub 2018 Jul 24.

PMID:
29989797
5.

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.

Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

J Alzheimers Dis. 2018;64(3):859-873. doi: 10.3233/JAD-180165.

PMID:
29966196
6.

Relevance of N-terminal residues for amyloid-β binding to platelet integrin αIIbβ3, integrin outside-in signaling and amyloid-β fibril formation.

Donner L, Gremer L, Ziehm T, Gertzen CGW, Gohlke H, Willbold D, Elvers M.

Cell Signal. 2018 Oct;50:121-130. doi: 10.1016/j.cellsig.2018.06.015. Epub 2018 Jun 30.

PMID:
29964150
7.

Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d-Peptides in the Interaction with Amyloid-Beta Monomers.

Ziehm T, Buell AK, Willbold D.

ACS Chem Neurosci. 2018 Jun 21. doi: 10.1021/acschemneuro.8b00132. [Epub ahead of print]

PMID:
29893543
8.

Proline Restricts Loop I Conformation of the High Affinity WW Domain from Human Nedd4-1 to a Ligand Binding-Competent Type I β-Turn.

Schulte M, Panwalkar V, Freischem S, Willbold D, Dingley AJ.

J Phys Chem B. 2018 Apr 19;122(15):4219-4230. doi: 10.1021/acs.jpcb.7b11637. Epub 2018 Apr 10.

PMID:
29595969
9.

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.

Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

J Alzheimers Dis. 2018;63(1):115-130. doi: 10.3233/JAD-170775.

10.

Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides.

Cavini IA, Munte CE, Erlach MB, van Groen T, Kadish I, Zhang T, Ziehm T, Nagel-Steger L, Kutzsche J, Kremer W, Willbold D, Kalbitzer HR.

Chem Commun (Camb). 2018 Mar 27;54(26):3294-3297. doi: 10.1039/c8cc01458b.

PMID:
29537428
11.

Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases.

Kulawik A, Heise H, Zafiu C, Willbold D, Bannach O.

FEBS Lett. 2018 Feb;592(4):516-534. doi: 10.1002/1873-3468.12983. Epub 2018 Feb 8. Review.

PMID:
29360176
12.

Biophysical insights from a single chain camelid antibody directed against the Disrupted-in-Schizophrenia 1 protein.

Yerabham ASK, Müller-Schiffmann A, Ziehm T, Stadler A, Köber S, Indurkhya X, Marreiros R, Trossbach SV, Bradshaw NJ, Prikulis I, Willbold D, Weiergräber OH, Korth C.

PLoS One. 2018 Jan 11;13(1):e0191162. doi: 10.1371/journal.pone.0191162. eCollection 2018.

13.

Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.

Dunkelmann T, Teichmann K, Ziehm T, Schemmert S, Frenzel D, Tusche M, Dammers C, Jürgens D, Langen KJ, Demuth HU, Shah NJ, Kutzsche J, Willuweit A, Willbold D.

Neuropeptides. 2018 Feb;67:27-35. doi: 10.1016/j.npep.2017.11.011. Epub 2017 Nov 27.

PMID:
29273382
14.

Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma.

Hupert M, Elfgen A, Schartmann E, Schemmert S, Buscher B, Kutzsche J, Willbold D, Santiago-Schübel B.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15;1073:123-129. doi: 10.1016/j.jchromb.2017.12.009. Epub 2017 Dec 8.

PMID:
29248770
15.

Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.

Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Joni Shah N, Langen KJ, Kutzsche J, Willbold D, Willuweit A.

Eur J Pharm Sci. 2018 Mar 1;114:93-102. doi: 10.1016/j.ejps.2017.12.005. Epub 2017 Dec 7.

PMID:
29225107
16.

Structure and interaction of Corynebacterium pseudotuberculosis cold shock protein A with Y-box single-stranded DNA fragment.

Caruso IP, Panwalkar V, Coronado MA, Dingley AJ, Cornélio ML, Willbold D, Arni RK, Eberle RJ.

FEBS J. 2018 Jan;285(2):372-390. doi: 10.1111/febs.14350. Epub 2017 Dec 29.

PMID:
29197185
17.

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.

van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D.

Sci Rep. 2017 Nov 24;7(1):16275. doi: 10.1038/s41598-017-16565-1.

18.

Structural insights into ion conduction by channelrhodopsin 2.

Volkov O, Kovalev K, Polovinkin V, Borshchevskiy V, Bamann C, Astashkin R, Marin E, Popov A, Balandin T, Willbold D, Büldt G, Bamberg E, Gordeliy V.

Science. 2017 Nov 24;358(6366). pii: eaan8862. doi: 10.1126/science.aan8862.

PMID:
29170206
19.

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.

Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D.

Molecules. 2017 Oct 10;22(10). pii: E1693. doi: 10.3390/molecules22101693.

20.

Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways.

Dammers C, Schwarten M, Buell AK, Willbold D.

Chem Sci. 2017 Jul 1;8(7):4996-5004. doi: 10.1039/c6sc04797a. Epub 2017 May 5.

21.

Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth.

Wördehoff MM, Shaykhalishahi H, Groß L, Gremer L, Stoldt M, Buell AK, Willbold D, Hoyer W.

J Mol Biol. 2017 Oct 13;429(20):3018-3030. doi: 10.1016/j.jmb.2017.09.005. Epub 2017 Sep 13.

22.

The Atg8 Family of Proteins-Modulating Shape and Functionality of Autophagic Membranes.

Abdollahzadeh I, Schwarten M, Gensch T, Willbold D, Weiergräber OH.

Front Genet. 2017 Aug 28;8:109. doi: 10.3389/fgene.2017.00109. eCollection 2017. Review.

23.

Fibril structure of amyloid-β(1-42) by cryo-electron microscopy.

Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli RBG, Tusche M, Lopez-Iglesias C, Hoyer W, Heise H, Willbold D, Schröder GF.

Science. 2017 Oct 6;358(6359):116-119. doi: 10.1126/science.aao2825. Epub 2017 Sep 7.

24.

Direct binding to GABARAP family members is essential for HIV-1 Nef plasma membrane localization.

Boeske A, Schwarten M, Ma P, Tusche M, Mötter J, Möller C, Neudecker P, Hoffmann S, Willbold D.

Sci Rep. 2017 Jul 20;7(1):5979. doi: 10.1038/s41598-017-06319-4.

25.

Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.

Elfgen A, Santiago-Schübel B, Gremer L, Kutzsche J, Willbold D.

Eur J Pharm Sci. 2017 Sep 30;107:203-207. doi: 10.1016/j.ejps.2017.07.015. Epub 2017 Jul 12.

PMID:
28711713
26.

Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.

Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D.

ACS Chem Neurosci. 2017 Sep 20;8(9):1889-1900. doi: 10.1021/acschemneuro.7b00045. Epub 2017 Jun 23.

PMID:
28581708
27.

1H, 13C, and 15N backbone and sidechain resonance assignments of a monomeric variant of E. coli deoxyribose-5-phosphate aldolase.

Schulte M, Stoldt M, Neudecker P, Pietruszka J, Willbold D, Panwalkar V.

Biomol NMR Assign. 2017 Oct;11(2):197-201. doi: 10.1007/s12104-017-9747-6. Epub 2017 May 30.

PMID:
28560616
28.

Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution.

Wolff M, Zhang-Haagen B, Decker C, Barz B, Schneider M, Biehl R, Radulescu A, Strodel B, Willbold D, Nagel-Steger L.

Sci Rep. 2017 May 30;7(1):2493. doi: 10.1038/s41598-017-02370-3.

29.

Fluorescence correlation spectroscopy reveals a cooperative unfolding of monomeric amyloid-β 42 with a low Gibbs free energy.

Schneider M, Walta S, Cadek C, Richtering W, Willbold D.

Sci Rep. 2017 May 19;7(1):2154. doi: 10.1038/s41598-017-02410-y.

30.

Mechanism of transmembrane signaling by sensor histidine kinases.

Gushchin I, Melnikov I, Polovinkin V, Ishchenko A, Yuzhakova A, Buslaev P, Bourenkov G, Grudinin S, Round E, Balandin T, Borshchevskiy V, Willbold D, Leonard G, Büldt G, Popov A, Gordeliy V.

Science. 2017 Jun 9;356(6342). pii: eaah6345. doi: 10.1126/science.aah6345. Epub 2017 May 18.

PMID:
28522691
31.

Multiple WW domains of Nedd4-1 undergo conformational exchange that is quenched upon peptide binding.

Panwalkar V, Neudecker P, Willbold D, Dingley AJ.

FEBS Lett. 2017 Jun;591(11):1573-1583. doi: 10.1002/1873-3468.12664. Epub 2017 May 22.

32.

Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.

Dammers C, Reiss K, Gremer L, Lecher J, Ziehm T, Stoldt M, Schwarten M, Willbold D.

Biophys J. 2017 Apr 25;112(8):1621-1633. doi: 10.1016/j.bpj.2017.03.007.

33.

Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.

Jaguva Vasudevan AA, Hofmann H, Willbold D, Häussinger D, Koenig BW, Münk C.

J Mol Biol. 2017 Apr 21;429(8):1171-1191. doi: 10.1016/j.jmb.2017.03.015. Epub 2017 Mar 16.

PMID:
28315663
34.

Investigating Structure and Dynamics of Atg8 Family Proteins.

Weiergräber OH, Schwarten M, Strodel B, Willbold D.

Methods Enzymol. 2017;587:115-142. doi: 10.1016/bs.mie.2016.09.056. Epub 2016 Dec 1. Review.

PMID:
28253952
35.

A structural organization for the Disrupted in Schizophrenia 1 protein, identified by high-throughput screening, reveals distinctly folded regions, which are bisected by mental illness-related mutations.

Yerabham ASK, Mas PJ, Decker C, Soares DC, Weiergräber OH, Nagel-Steger L, Willbold D, Hart DJ, Bradshaw NJ, Korth C.

J Biol Chem. 2017 Apr 21;292(16):6468-6477. doi: 10.1074/jbc.M116.773903. Epub 2017 Mar 1.

36.

Erratum to: High-Resolution Structure of a Membrane Protein Transferred from Amphipol to a Lipidic Mesophase.

Polovinkin V, Gushchin I, Sintsov M, Round E, Balandin T, Chervakov P, Shevchenko V, Utrobin P, Popov A, Borshchevskiy V, Mishin A, Kuklin A, Willbold D, Chupin V, Popot JL, Gordeliy V.

J Membr Biol. 2017 Apr;250(2):237. doi: 10.1007/s00232-017-9949-y. No abstract available.

PMID:
28229180
37.

Structure of a LOV protein in apo-state and implications for construction of LOV-based optical tools.

Arinkin V, Granzin J, Röllen K, Krauss U, Jaeger KE, Willbold D, Batra-Safferling R.

Sci Rep. 2017 Feb 17;7:42971. doi: 10.1038/srep42971.

38.

Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies.

Herrmann Y, Bujnicki T, Zafiu C, Kulawik A, Kühbach K, Peters L, Fabig J, Willbold J, Bannach O, Willbold D.

Clin Chim Acta. 2017 Mar;466:152-159. doi: 10.1016/j.cca.2017.01.010. Epub 2017 Jan 11.

PMID:
28088342
39.

Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.

Dammers C, Yolcu D, Kukuk L, Willbold D, Pickhardt M, Mandelkow E, Horn AH, Sticht H, Malhis MN, Will N, Schuster J, Funke SA.

PLoS One. 2016 Dec 22;11(12):e0167432. doi: 10.1371/journal.pone.0167432. eCollection 2016.

40.

High-Affinity Binding of Monomeric but Not Oligomeric Amyloid-β to Ganglioside GM1 Containing Nanodiscs.

Thomaier M, Gremer L, Dammers C, Fabig J, Neudecker P, Willbold D.

Biochemistry. 2016 Dec 6;55(48):6662-6672. Epub 2016 Nov 18.

PMID:
27933798
41.

sFIDA automation yields sub-femtomolar limit of detection for Aβ aggregates in body fluids.

Herrmann Y, Kulawik A, Kühbach K, Hülsemann M, Peters L, Bujnicki T, Kravchenko K, Linnartz C, Willbold J, Zafiu C, Bannach O, Willbold D.

Clin Biochem. 2017 Mar;50(4-5):244-247. doi: 10.1016/j.clinbiochem.2016.11.001. Epub 2016 Nov 5.

PMID:
27823959
42.

IQGAP1 Interaction with RHO Family Proteins Revisited: KINETIC AND EQUILIBRIUM EVIDENCE FOR MULTIPLE DISTINCT BINDING SITES.

Nouri K, Fansa EK, Amin E, Dvorsky R, Gremer L, Willbold D, Schmitt L, Timson DJ, Ahmadian MR.

J Biol Chem. 2016 Dec 16;291(51):26364-26376. Epub 2016 Nov 4.

43.

Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay.

Kravchenko K, Kulawik A, Hülsemann M, Kühbach K, Zafiu C, Herrmann Y, Linnartz C, Peters L, Bujnicki T, Willbold J, Bannach O, Willbold D.

Biol Chem. 2017 Apr 1;398(4):465-475. doi: 10.1515/hsz-2016-0153.

PMID:
27811340
44.

Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.

Koch K, Hartmann R, Schröter F, Suwala AK, Maciaczyk D, Krüger AC, Willbold D, Kahlert UD, Maciaczyk J.

Oncotarget. 2016 Nov 8;7(45):73414-73431. doi: 10.18632/oncotarget.12337.

45.

β-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation Inhibitor.

Mirecka EA, Feuerstein S, Gremer L, Schröder GF, Stoldt M, Willbold D, Hoyer W.

Sci Rep. 2016 Sep 19;6:33474. doi: 10.1038/srep33474.

46.

Biofunctionalized Silica Nanoparticles: Standards in Amyloid-β Oligomer-Based Diagnosis of Alzheimer's Disease.

Hülsemann M, Zafiu C, Kühbach K, Lühmann N, Herrmann Y, Peters L, Linnartz C, Willbold J, Kravchenko K, Kulawik A, Willbold S, Bannach O, Willbold D.

J Alzheimers Dis. 2016 Jul 27;54(1):79-88. doi: 10.3233/JAD-160253.

PMID:
27472876
47.

Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.

Jiang N, Frenzel D, Schartmann E, van Groen T, Kadish I, Shah NJ, Langen KJ, Willbold D, Willuweit A.

Biochim Biophys Acta. 2016 Nov;1858(11):2717-2724. doi: 10.1016/j.bbamem.2016.07.002. Epub 2016 Jul 14.

48.

Data describing the solution structure of the WW3* domain from human Nedd4-1.

Panwalkar V, Schulte M, Lecher J, Stoldt M, Willbold D, Dingley AJ.

Data Brief. 2016 Jun 22;8:605-12. doi: 10.1016/j.dib.2016.06.024. eCollection 2016 Sep.

49.

Characterizing the Effect of Multivalent Conjugates Composed of Aβ-Specific Ligands and Metal Nanoparticles on Neurotoxic Fibrillar Aggregation.

Streich C, Akkari L, Decker C, Bormann J, Rehbock C, Müller-Schiffmann A, Niemeyer FC, Nagel-Steger L, Willbold D, Sacca B, Korth C, Schrader T, Barcikowski S.

ACS Nano. 2016 Aug 23;10(8):7582-97. doi: 10.1021/acsnano.6b02627. Epub 2016 Jul 20.

PMID:
27404114
50.

Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity.

Rudolph S, Klein AN, Tusche M, Schlosser C, Elfgen A, Brener O, Teunissen C, Gremer L, Funke SA, Kutzsche J, Willbold D.

PLoS One. 2016 Jul 12;11(7):e0159470. doi: 10.1371/journal.pone.0159470. eCollection 2016.

Supplemental Content

Loading ...
Support Center